Innovative Therapy to Treat Women With Angina With Nonobstructive Coronary Artery Disease (ANOCA) and Coronary Microvascular Disease
University of Virginia
Summary
The goal of this clinical trial is to that Sodium-glucose cotransporter 2 inhibitors treatment will improve Coronary Microvascular Disease with anginal symptoms associated with non-obstructive coronary disease in women. The main questions it aims to answer are: Aim 1: Test the hypothesis that Sodium-glucose cotransporter 2 inhibitors treatment improves coronary microvascular disease in women with no evidence of epicardial obstructive coronary artery disease. Aim 2: Test the hypothesis that Sodium-glucose cotransporter 2 inhibitors treatment improves angina symptoms and other quality of life measurements associated with the improvement of CFR. AIM 3: Identify the effect of Sodium-glucose cotransporter 2 inhibition on inflammation pathways and markers of systemic Research will compare Brezavvy to placebo Participants will: * Take study drug or placebo for 12 weeks * Stress Cardiac magnetic resonance imaging * 12 lead electrocardiograms * Complete questionnaires
Description
Cardio microvascular disease is defined as epicardial and/or microvascular endothelial and/or non-endothelial dysfunction that limits myocardial perfusion, most often detected as reduced coronary flow reserve (CFR). CFR, which is calculated as the ratio of hyperemic to resting absolute myocardial blood flow, indicates the myocardium's ability to increase flow in response to stress or vasodilation. Because the coronary microcirculation is beyond the resolution of invasive or non-invasive coronary angiography, direct interrogation of coronary microvascular function is necessary to establish the…
Eligibility
- Age range
- 18+ years
- Sex
- Female
- Healthy volunteers
- No
Inclusion Criteria: * • Female sex. * Age ≥18 years. * Willing and able to provide written informed consent. * Signs and symptoms of suspected ischemia prompted referral for further evaluation by cardiac catheterization or CCTA within two years of consent. * No evidence of obstructive epicardial CAD (stenosis \<50%) of a major epicardial vessel or an FFR ≤0.80 by invasive catheterization or CCTA. Patients who have not undergone cardiac catheterization of CT angiogram within the last 2 years for chest pain can be scheduled for a screening CT angiogram of the coronary arteries to confi…
Interventions
- DrugBrezavvy 20Mg Oral Tablet
Brezavvy 20mg oral
- DrugPlacebo
Placebo tablet given to subject vs. active drug.
Location
- UVA HealthCharlottesville, Virginia